Intravenous cisplatin for superficial bladder tumors

Publisher Website
Google Scholar
Abstract
Cisplatin, 1.25 mg/kg IV QM, was administered to 15 patients with recurrent flat carcinoma in situ and/or bladder tumors confined to the mucosa and lamina propria. All patients had a history of multiple transurethral resection and 4 had received prior irradiation and two prior intravesical thiophosphoramide. Response was evaluated by urinary cytologic findings, cystoscopy and biopsy. Of 14 adequately treated cases, four (28%) had disappearence of all visible lesions, cystoscopically, for a median of eight months (range, 8–18), and six exhibited transiently a >50% decrease in the number of tumors. However, no patient demonstrated a complete remission—all had persistently positive urinary cytologies. Nausea and vomiting, even at this dose level, was significant and at times, severe. Cisplatin, in the dose and schedule used, was found to be ineffective in controlling low-stage bladder tumors. Cancer 50:1722-1723, 1982.

This publication has 2 references indexed in Scilit: